MX345287B - Nuevas composiciones para tratar cmt y trastornos relacionados. - Google Patents
Nuevas composiciones para tratar cmt y trastornos relacionados.Info
- Publication number
- MX345287B MX345287B MX2011012817A MX2011012817A MX345287B MX 345287 B MX345287 B MX 345287B MX 2011012817 A MX2011012817 A MX 2011012817A MX 2011012817 A MX2011012817 A MX 2011012817A MX 345287 B MX345287 B MX 345287B
- Authority
- MX
- Mexico
- Prior art keywords
- related disorders
- new compositions
- treating cmt
- cmt
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
La presente invención se refiere a composiciones y a procedimientos para el tratamiento de la enfermedad de Charcot-Marie-Tooth y trastornos relacionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305506A EP2263665A1 (en) | 2009-06-02 | 2009-06-02 | New compositions for treating CMT and related disorders |
PCT/EP2010/057438 WO2010139627A1 (en) | 2009-06-02 | 2010-05-28 | New compositions for treating cmt and related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011012817A MX2011012817A (es) | 2011-12-16 |
MX345287B true MX345287B (es) | 2017-01-24 |
Family
ID=41168603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011012817A MX345287B (es) | 2009-06-02 | 2010-05-28 | Nuevas composiciones para tratar cmt y trastornos relacionados. |
Country Status (26)
Country | Link |
---|---|
US (4) | US20120088744A1 (es) |
EP (4) | EP2263665A1 (es) |
JP (1) | JP5875191B2 (es) |
KR (1) | KR101740336B1 (es) |
CN (2) | CN104688737B (es) |
AR (1) | AR077540A1 (es) |
AU (1) | AU2010255802B2 (es) |
BR (1) | BRPI1013302B1 (es) |
CA (1) | CA2763495C (es) |
CY (1) | CY1115736T1 (es) |
DK (1) | DK2437742T3 (es) |
EA (1) | EA024523B1 (es) |
ES (2) | ES2523268T3 (es) |
HK (2) | HK1206590A1 (es) |
HR (1) | HRP20141009T1 (es) |
IL (1) | IL216621A (es) |
MX (1) | MX345287B (es) |
NZ (1) | NZ596656A (es) |
PL (1) | PL2437742T3 (es) |
PT (1) | PT2437742E (es) |
SG (1) | SG176275A1 (es) |
SI (1) | SI2437742T1 (es) |
SM (1) | SMT201400160B (es) |
UA (1) | UA110013C2 (es) |
WO (1) | WO2010139627A1 (es) |
ZA (1) | ZA201109423B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
EP2263665A1 (en) * | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
US9867837B2 (en) * | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
SI2796132T1 (sl) | 2011-03-01 | 2018-09-28 | Pharnext | Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu |
US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
FR2987271B1 (fr) * | 2012-02-28 | 2017-08-18 | Hra Pharma Lab | Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens |
WO2014163380A1 (ko) * | 2013-04-02 | 2014-10-09 | 사회복지법인 삼성생명공익재단 | 샤르코-마리-투스 질환 치료제의 스크리닝 방법 및 이에 이용되는 자가분화운동신경세포 |
CA2913331C (en) | 2013-06-05 | 2021-08-24 | Pharnext | Stable oral solutions for combined api |
RU2686110C1 (ru) | 2013-12-13 | 2019-04-24 | Пьер Фабр Медикамент | Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра |
EP3104850A1 (en) | 2014-02-11 | 2016-12-21 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
EA201691703A1 (ru) * | 2014-02-24 | 2017-04-28 | Фарнекст | Новые композиции для лечения механических повреждений нервов |
WO2016191241A1 (en) * | 2015-05-27 | 2016-12-01 | Mmc & Company Llc | Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
CN111658643B (zh) * | 2020-07-31 | 2021-12-07 | 西安交通大学医学院第一附属医院 | 雷帕霉素在难治性Graves病中的制药应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW427904B (en) * | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
AU9187598A (en) * | 1997-09-30 | 1999-04-23 | Daiichi Pharmaceutical Co., Ltd. | Oral preparation |
WO2000020024A2 (en) | 1998-10-02 | 2000-04-13 | Celtrix Pharmaceuticals, Inc. | Methods for the treatment of non-thyroid disorders |
WO2002049607A2 (en) | 2000-12-20 | 2002-06-27 | Firmenich Sa | Flavoured oral drug delivery system |
JP3805646B2 (ja) * | 2001-05-25 | 2006-08-02 | 久光メディカル株式会社 | 医薬液剤 |
CN1652752A (zh) | 2002-03-14 | 2005-08-10 | 欧罗赛铁克股份有限公司 | 盐酸纳曲酮组合物 |
FR2842422B1 (fr) * | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
WO2004019938A1 (en) | 2002-08-28 | 2004-03-11 | Merck Frosst Canada & Co. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
US20050038062A1 (en) | 2003-04-14 | 2005-02-17 | Burns Lindsay H. | Methods and materials for the treatment of pain comprising opioid antagonists |
WO2004103263A2 (en) | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
MXPA06003392A (es) | 2003-09-25 | 2006-06-08 | Euro Celtique Sa | Combinacion farmaceutica de hidrocodona y naltrexona. |
CA2537029C (en) * | 2003-11-26 | 2013-03-12 | Likan Liang | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
FR2865648B1 (fr) | 2004-02-03 | 2006-06-30 | Philippe Perovitch | Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede |
US20050220863A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist |
JP2006131545A (ja) | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | 神経因性疼痛治療剤 |
GB0509052D0 (en) * | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
DE102006016990A1 (de) | 2006-04-11 | 2007-10-18 | Hermann, Holger Lars, Dr. | Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2117517B1 (en) | 2007-01-11 | 2011-06-01 | XenoPort, Inc. | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
US20080255062A1 (en) | 2007-02-13 | 2008-10-16 | University Of Manitoba | Axon regeneration from adult sensory neurons |
EP2065821A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | Novel disease treatment by predicting drug association |
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
EP2135607A1 (en) * | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2322163A1 (en) | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
IT1400067B1 (it) | 2010-05-21 | 2013-05-17 | Molteni & C | Spray nasale liquido contenente naltrexone a bassi dosaggi. |
SI2796132T1 (sl) | 2011-03-01 | 2018-09-28 | Pharnext | Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu |
CA2913331C (en) | 2013-06-05 | 2021-08-24 | Pharnext | Stable oral solutions for combined api |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
-
2009
- 2009-06-02 EP EP09305506A patent/EP2263665A1/en not_active Withdrawn
-
2010
- 2010-05-28 EP EP10724399.0A patent/EP2437742B1/en active Active
- 2010-05-28 JP JP2012513558A patent/JP5875191B2/ja active Active
- 2010-05-28 ES ES10724399.0T patent/ES2523268T3/es active Active
- 2010-05-28 CN CN201510024891.9A patent/CN104688737B/zh active Active
- 2010-05-28 AU AU2010255802A patent/AU2010255802B2/en active Active
- 2010-05-28 DK DK10724399.0T patent/DK2437742T3/da active
- 2010-05-28 CN CN201080024444.9A patent/CN102458387B/zh active Active
- 2010-05-28 PT PT107243990T patent/PT2437742E/pt unknown
- 2010-05-28 US US13/375,288 patent/US20120088744A1/en not_active Abandoned
- 2010-05-28 EA EA201101686A patent/EA024523B1/ru not_active IP Right Cessation
- 2010-05-28 NZ NZ596656A patent/NZ596656A/xx unknown
- 2010-05-28 WO PCT/EP2010/057438 patent/WO2010139627A1/en active Application Filing
- 2010-05-28 EP EP14176796.2A patent/EP2823817B1/en not_active Not-in-force
- 2010-05-28 SI SI201030781T patent/SI2437742T1/sl unknown
- 2010-05-28 MX MX2011012817A patent/MX345287B/es active IP Right Grant
- 2010-05-28 CA CA2763495A patent/CA2763495C/en active Active
- 2010-05-28 KR KR1020117029978A patent/KR101740336B1/ko active IP Right Grant
- 2010-05-28 SG SG2011087889A patent/SG176275A1/en unknown
- 2010-05-28 UA UAA201115274A patent/UA110013C2/ru unknown
- 2010-05-28 EP EP17177004.3A patent/EP3246025A1/en not_active Withdrawn
- 2010-05-28 ES ES14176796.2T patent/ES2641191T3/es active Active
- 2010-05-28 PL PL10724399T patent/PL2437742T3/pl unknown
- 2010-05-28 BR BRPI1013302-0A patent/BRPI1013302B1/pt active IP Right Grant
- 2010-06-02 AR ARP100101934A patent/AR077540A1/es not_active Application Discontinuation
-
2011
- 2011-11-27 IL IL216621A patent/IL216621A/en active IP Right Grant
- 2011-12-21 ZA ZA2011/09423A patent/ZA201109423B/en unknown
-
2012
- 2012-10-11 HK HK15106188.2A patent/HK1206590A1/xx not_active IP Right Cessation
- 2012-10-11 HK HK12110036.1A patent/HK1170150A1/xx unknown
-
2014
- 2014-10-21 HR HRP20141009AT patent/HRP20141009T1/hr unknown
- 2014-10-30 SM SM201400160T patent/SMT201400160B/xx unknown
- 2014-11-04 CY CY20141100914T patent/CY1115736T1/el unknown
-
2016
- 2016-04-25 US US15/137,801 patent/US9427436B1/en active Active
-
2018
- 2018-05-02 US US15/969,568 patent/US10905686B2/en active Active
-
2020
- 2020-12-23 US US17/132,547 patent/US11672796B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX345287B (es) | Nuevas composiciones para tratar cmt y trastornos relacionados. | |
EP2293800A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES | |
EP2440222A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES AND CONDITIONS OF THE BRAIN | |
MX2019011905A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
MX2011009690A (es) | Métodos y composiciones para trastornos relacionados con la proliferación celurar. | |
MY163275A (en) | Ibat inhibitors for the treatment of liver diseases | |
IN2012DN03883A (es) | ||
TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
IN2012DN00624A (es) | ||
MX353299B (es) | Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. | |
PT2300614E (pt) | Métodos e composições para tratamento de distúrbios mitocondriais | |
EP2515926A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS-RELATED OPHTHALMIC DISEASES | |
IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
UA107666C2 (uk) | Застосування l-серину як лікарського засобу для попередження та/або лікування свербіжу шкіри | |
MX2015003701A (es) | Composiciones para tratamiento. | |
IL214745A0 (en) | Treatment of insulin-resistant disorders | |
EP2490721A4 (en) | COMPOSITIONS, TREATMENT PROCEDURES AND DIAGNOSIS OF AUTOIMMUN-MEDIATED ILLNESSES AND METHOD FOR THE PREPARATION OF SUCH COMPOSITIONS | |
EP2675275A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | |
EP4070794A3 (en) | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders | |
MX2012007142A (es) | Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea. | |
PL2375912T3 (pl) | Kompozycje i sposoby leczenia uczucia dyskomfortu gardła | |
HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
MX2011013324A (es) | Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor. | |
EP2569018A4 (en) | HUMANIZED TTC AND METHOD FOR ITS USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |